188 E. Blaine Street, Suite 200, Seattle, Washington 98102
Ernst & Young, LLP
December 31st.
In 2017, Alpine Immune Sciences, Inc. completed a reverse merger to become a publicly listed company on the NASDAQ stock exchange.
Shares are traded on the NASDAQ stock exchange.
Alpine Immune Sciences does not expect to declare or pay any cash or other dividends on our common stock, as we intend to reinvest cash flow generated by operations into our business.
The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc., 1717 Arch Street, Suite 1300, Philadelphia, PA 19103.
Alpine Immune Sciences does not have a direct stock purchase plan.
ir@alpineimmunesciences.com
SEC Filings.
010392595
Visit Email Alerts.